

West Virginia Medicaid Drug Utilization Review Board Minutes Sep 20, 2023

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Mary Nemeth-Pyles, MSN, RN, CS
Ernest Miller, DO

Members Absent:

C.K. Babcock, PharmD

DHHR/BMS Staff:

Vicki Cunningham, PharmD, Director of Pharmacy Services
Gail Goodnight, RPh, Rebate Manager
Lori Moles, PharmD
Priya Shah, PharmD, Drug Utilization Review Coordinator
Doug Sorvig, Data Analyst

Contract Staff:

Jeffrey Barkin, MD – Change Healthcare
Joe Bergondo, PharmD – Change Healthcare
Laureen Biczak, MD – Change Healthcare
Eric Sears, RPh, Gainwell
Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Cory Chambliss, Acentra
Scott Donald, PharmD, Acentra
Alena Mitchell PharmD, Acentra

1. INTRODUCTIONS

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:01 pm EST. The DUR Board and others introduced themselves.
- b. Vicki Cunningham informed the Board of the recent death of a former DUR Board member, Kc Lovin. Members of the Board expressed appreciation for Kc's contributions to the Medicaid program and the community she served as a physician's assistant and condolences to her family.

2. **APPROVAL OF MINUTES FROM May 24th, 2023 DUR BOARD MEETING**
 - a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.
3. **OLD BUSINESS**
 - a. None
4. **NEW BUSINESS**
 - a. **Speakers**
 - i. None
 - b. **Updates from May 24th, 2023 P&T Committee Meeting**
 - i. Dr. Joe Bergondo presented the PDL status updates from the May 24th, 2023 P&T meeting.
 - c. **Prior Authorization Criteria.** Attachment A
 - i. **Atorvaliq:** approved as presented.
 - ii. **Beriner/HAE treatment agents:** approved with modifications.
 - iii. **HAE prophylactic agents:** approved as presented.
 - iv. **Liqrev:** approved as presented.
 - v. **Zavzpret:** approved as presented.
 - vi. **Vowst:** approved with modifications.
 - vii. **Synagis:** approved as presented.
5. **REPORTS – 2nd Quarter of 2023**
 - a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2023 Second Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
 - b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the Second Quarter of 2023. Attachment C
 - c. **Acentra:** Dr. Alena Mitchell presented a summary of the RDUR interventions for the Second Quarter of 2023. Attachment D
6. **OTHER BUSINESS**
 - a. None
7. **NEXT MEETING AND ADJOURNMENT**
 - a. The meeting concluded at 5:03 pm EST.
 - b. The next meeting will be November 15th, 2023, from 4-6pm (EST) on a virtual platform.